Podcasts

E-Books

Videos

Articles

Business & Practice

Meir Rinde, MS, is a freelance print and radio journalist based in Philadelphia, Pennsylvania.

Researchers report findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings. 

Study: Medicare Consolidated Biosimilar Payment Codes Would Save Money

Tony Hagen is senior managing editor for The Center for Biosimilars

In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029. 

NJ Court Decision Means 3 Decades of Product Exclusivity for Enbrel

Regulators are at work clarifying biosimilar guidance and on Capitol Hill, a battle is raging over reforms that could help or hurt biosimilar advancement.

Biosimilars Roundup: November Was Dominated by Legislative and Regulatory News 

Specialty tiers for biosimilars and reforms that address the proliferation of poor-quality patents would help lower costs and improve access, biosimilar industry veterans said.

Biosimilar Industry Critiques Biden's Drug Pricing Reforms

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

An expert on biotherapeutics recommends more science be applied to World Health Organization (WHO) biosimilar guideline revisions. 

Opinion: One Step Forward, Half a Step Back for WHO Biosimilar Guidance 

Authors of a review discuss barriers to insulin access and potential solutions as the 100-year anniversary of the drug's first use for diabetes gets closer. 

High Cost, Low Access Still Plague Insulin Market at 100-Year Anniversary

Progression-free survival (PFS) was improved for patients with epidermal growth factor receptor–mutated nonsquamous non–small cell lung cancer who were treated with PD-1 and antivascularization therapy.

Sintilimab and Bevacizumab Biosimilar Improve PFS in Advanced Lung Cancer

The utilization rates for biosimilars in community oncology have been much higher than for other disease categories and are only expected to rise, says Steven Yates, MD.

Dr Steven Yates Discusses the Need for Biosimilar Incentives in Community Oncology

European Medicines Agency (EMA) officials said their pilot was based on wrong assumptions about the biosimilar development process. 

EMA Reports on Pilot Study of Biosimilar Development Tailoring 

The World Health Organization (WHO) has issued a fresh draft of its biosimilar evaluation guidelines. Medicines for Europe science and policy expert Marta Baldrighi, PhD, explains the significance. 

Regulatory